Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELOXATIN vs BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxaliplatin undergoes non-enzymatic biotransformation to form platinum-DNA adducts, leading to inhibition of DNA replication and transcription, and ultimately cell death. It is a third-generation platinum-based alkylating agent.
Bacitracin zinc inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin sulfate and polymyxin B sulfate are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to 30S ribosomal subunit and causes misreading of m RNA, while polymyxin B disrupts bacterial cell membrane permeability by interacting with phospholipids.
Adjuvant treatment of stage III colon cancer after complete resection of primary tumor,Treatment of advanced colorectal cancer in combination with 5-fluorouracil and leucovorin
Topical treatment of bacterial infections of the skin and eye (e.g., conjunctivitis, keratitis, blepharitis),Prophylaxis of minor wounds, cuts, and abrasions
85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks (adjuvant); 85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks or 130 mg/m2 IV over 2 hours on day 1, repeated every 3 weeks (advanced disease).
Apply topically (ointment or cream) to affected area 1-3 times daily. For ophthalmic use, instill 1-2 drops into affected eye(s) every 3-4 hours.
Terminal half-life of ultrafilterable platinum: ~10-27 hours (mean ~14 hours); total platinum: ~40-50 hours. Clinical context: prolonged exposure due to tissue binding.
Neomycin: 2-3 h; polymyxin B: 4.5-6 h; bacitracin: 1.5 h. Combined: effectively ~2-6 h depending on renal function; clinical context: prolonged with renal impairment.
Oxaliplatin undergoes rapid non-enzymatic biotransformation in plasma and tissues to form active platinum derivatives, primarily via displacement of the oxalate ligand. Minimal hepatic metabolism; elimination is predominantly renal.
Not systemically absorbed after topical administration; no significant metabolism.
Renal: ~54% of platinum excreted in urine within 48 hours; fecal: small amount (<2%); biliary excretion is minimal.
Neomycin: ~99% renal; polymyxin B: ~60% renal, 40% fecal; bacitracin: mainly renal (over 90%). Combined: renal (predominant), with minor biliary/fecal contribution (polymyxin B).
Platinum binds >90% to plasma proteins, mainly albumin and gamma-globulins; irreversible binding.
Neomycin: 0-20%; polymyxin B: 60-80% (alpha-1-acid glycoprotein, albumin); bacitracin: <5%. Combined: ~40-50% bound overall.
Vd of ultrafilterable platinum: ~0.4-0.6 L/kg; total platinum: ~4-6 L/kg, indicating extensive tissue distribution.
Neomycin: ~0.25 L/kg; polymyxin B: ~0.5 L/kg; bacitracin: ~0.3 L/kg. Combined Vd ~0.3-0.5 L/kg, reflecting limited distribution mainly to extracellular fluid.
Oral: Not bioavailable (unstable in GI tract); IV: 100%.
Topical/ophthalmic/otic: negligible systemic absorption (<0.1%).
Cr Cl ≥60 m L/min: No adjustment; Cr Cl 50-59 m L/min: No adjustment; Cr Cl 40-49 m L/min: Administer 85 mg/m2, but no data for 130 mg/m2; Cr Cl 30-39 m L/min: Administer 85 mg/m2 with caution, no data for 130 mg/m2; Cr Cl 20-29 m L/min: Administer 85 mg/m2 with extreme caution, no data for 130 mg/m2; Cr Cl <20 m L/min: Not recommended.
No systemic absorption with typical topical use; no adjustment necessary. For extensive use on damaged skin, monitor renal function and adjust if needed; no specific GFR-based guidelines.
Child-Pugh A: No adjustment required; Child-Pugh B: No adjustment required; Child-Pugh C: Use with caution; no specific dose reduction defined.
No adjustment needed for topical use. No systemic effects expected.
Not approved for pediatric use. No established dosing guidelines.
Same as adult dosing for topical use. For neonates, use with caution on large surface areas; avoid prolonged use.
No specific dose adjustment recommended based on age alone; monitor renal function and adjust according to calculated creatinine clearance.
No specific age-related adjustments. Use with caution on fragile skin; apply sparingly to avoid systemic absorption.
Anaphylactic-like reactions to oxaliplatin have been reported, which may occur within minutes of administration and require immediate discontinuation and symptomatic treatment. Oxaliplatin should be discontinued if severe hypersensitivity occurs.
None.
Hypersensitivity reactions (including anaphylaxis) have been reported and may be life-threatening. Discontinue permanently if severe reaction occurs.,Peripheral neuropathy, which may be acute (reversible) or chronic (persistent), is dose-limiting and requires dose adjustment or discontinuation.,Hepatotoxicity, including hepatic sinusoidal obstruction syndrome, has been reported. Monitor liver function.,Pulmonary toxicity, including pulmonary fibrosis, has been observed. Discontinue if interstitial lung disease is suspected.,Bleeding risk due to thrombocytopenia; monitor platelet counts.,Rhabdomyolysis has been reported; monitor for muscle pain/weakness.,Post-marketing reports of reversible posterior leukoencephalopathy syndrome (RPLS); discontinue if symptoms occur.
Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Neomycin is ototoxic and nephrotoxic if absorbed systemically (e.g., applied to large areas of damaged skin).,Avoid contact with eyes other than for ophthalmic use.,Cross-allergenicity among aminoglycosides exists.
History of severe hypersensitivity to oxaliplatin or any components of the formulation,Severe renal impairment (creatinine clearance <30 m L/min),Bone marrow suppression with baseline neutrophil count <1.5 × 10^9/L or platelet count <75 × 10^9/L,Pregnancy (can cause fetal harm)
Hypersensitivity to any component of the product.,Otic use if tympanic membrane is perforated (risk of ototoxicity).
Avoid cold food and beverages for 48 hours post-infusion to prevent acute neuropathy exacerbation. No known specific food-drug interactions; however, avoid grapefruit juice if taking CYP3A4-metabolized drugs (not oxaliplatin itself). Maintain adequate hydration; no restriction with normal meals.
No known food interactions with topical application.
Eloxatin (oxaliplatin) is a platinum-based antineoplastic agent classified as FDA Pregnancy Category D. There is evidence of fetal harm based on animal studies and its mechanism of action (DNA cross-linking). Use during pregnancy is contraindicated unless maternal benefit outweighs risk. First trimester exposure carries highest risk of major malformations; second and third trimester exposure may cause fetal growth restriction, myelosuppression, and neurotoxicity.
No evidence of teratogenicity in first trimester; animal studies show no fetal harm. Second and third trimester risk is low due to minimal systemic absorption from topical use. No known association with congenital anomalies.
It is unknown whether oxaliplatin or its metabolites are excreted in human milk. Due to potential serious adverse reactions in nursing infants, including myelosuppression and neurotoxicity, breastfeeding is not recommended during treatment and for at least 3 months after the last dose. No M/P ratio data available.
Minimal systemic absorption suggests negligible excretion into breast milk; M/P ratio not determined. Considered compatible with breastfeeding by AAP; avoid application to breast area to prevent infant ingestion.
No established dosing adjustments for pregnancy. Physiological changes (increased volume of distribution, altered hepatic metabolism, enhanced renal clearance) may reduce drug exposure. However, due to teratogenicity, use is not recommended. If deemed necessary, therapeutic drug monitoring is not standard and dose adjustments should be made based on clinical response and toxicity, with cautious monitoring of side effects.
No dosage adjustment required for topical use; systemic absorption is negligible. Use standard dosing as per non-pregnant adults.
Eloxatin (oxaliplatin) causes acute and chronic peripheral neuropathy; acute symptoms are triggered by cold exposure. Premedicate with antiemetics (e.g., aprepitant, dexamethasone, 5-HT3 antagonist) and avoid cold drinks or ice during infusion and for 48 hours thereafter. Monitor for laryngopharyngeal dysesthesia with cold exposure. Do not use aluminum-containing needles or IV sets as they degrade platinum compounds. Oxaliplatin is not compatible with chloride-containing solutions; dilute only in 5% dextrose in water. Assess renal function and reduce dose if Cr Cl < 30 m L/min.
OTC triple antibiotic ointment; avoid use on deep wounds, puncture wounds, or animal bites due to risk of toxicity and lack of efficacy. Neomycin carries the highest risk of allergic contact dermatitis among topical antibiotics; consider patch testing if prolonged use needed. Polymyxin B can cause neurotoxicity and nephrotoxicity if applied to large wounds or damaged skin. Not for use in eyes, ears, or mucous membranes. Do not exceed 7 days of continuous use.
Avoid cold drinks, ice, and cold temperatures during and for 2 days after infusion to prevent severe tingling or throat discomfort.,Report any numbness, tingling, or pain in hands/feet that interferes with daily activities or does not improve between cycles.,Take anti-nausea medications as prescribed before each infusion; call your doctor if vomiting persists.,Watch for signs of allergic reaction: rash, hives, difficulty breathing, swelling of face/lips/tongue.,Do not touch infusion tubing or eat ice chips during treatment due to cold sensitivity.
Clean the affected area before applying a thin layer of ointment 1-3 times daily.,Do not use on large areas of skin, deep cuts, puncture wounds, or animal bites unless directed by a doctor.,Do not apply to eyes, nose, mouth, or inside ears.,Stop use and consult a doctor if rash or allergic reaction develops, condition worsens, or persists for more than 7 days.,Keep out of reach of children; seek medical attention if accidentally ingested.
No interactions on record
"Cisatracurium, a non-depolarizing neuromuscular blocking agent (NMBA), competitively blocks nicotinic acetylcholine receptors at the neuromuscular junction, causing skeletal muscle paralysis. Polymyxin B, a polypeptide antibiotic, can potentiate this neuromuscular blockade by reducing presynaptic acetylcholine release and stabilizing postsynaptic membranes, leading to prolonged and enhanced neuromuscular blockade. This interaction increases the risk of prolonged muscle paralysis, respiratory depression, and apnea, especially in patients with renal impairment or those receiving other NMBAs."
"Mecamylamine, a ganglionic blocking agent, potentiates the neuromuscular blocking effects of Polymyxin B, a polypeptide antibiotic. This interaction occurs through additive or synergistic inhibition of neuromuscular transmission, potentially leading to prolonged or intensified muscle relaxation, respiratory depression, and apnea. The clinical outcome may include enhanced toxicity, especially in patients with renal impairment or those receiving concurrent anesthetics or other neuromuscular blocking agents."
"Decamethonium, a depolarizing neuromuscular blocker, enhances the neuromuscular blocking effects of Polymyxin B, a polypeptide antibiotic that can also cause neuromuscular blockade via direct membrane stabilization and calcium channel inhibition. This additive pharmacodynamic interaction can lead to prolonged or enhanced muscle weakness, potentially resulting in respiratory paralysis and apnea. Clinically, this combination increases the risk of acute respiratory failure and may prolong recovery from neuromuscular blockade."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELOXATIN vs BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, answered by our medical review team.
ELOXATIN is a Platinum-Based Antineoplastic that works by Oxaliplatin undergoes non-enzymatic biotransformation to form platinum-DNA adducts, leading to inhibition of DNA replication and transcription, and ultimately cell death. It is a third-generation platinum-based alkylating agent.. BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE is a Aminoglycoside Antibiotic that works by Bacitracin zinc inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin sulfate and polymyxin B sulfate are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to 30S ribosomal subunit and causes misreading of m RNA, while polymyxin B disrupts bacterial cell membrane permeability by interacting with phospholipids.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELOXATIN and BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELOXATIN is: 85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks (adjuvant); 85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks or 130 mg/m2 IV over 2 hours on day 1, repeated every 3 weeks (advanced disease).. The standard adult dose of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE is: Apply topically (ointment or cream) to affected area 1-3 times daily. For ophthalmic use, instill 1-2 drops into affected eye(s) every 3-4 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELOXATIN and BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELOXATIN is classified as Category C. Eloxatin (oxaliplatin) is a platinum-based antineoplastic agent classified as FDA Pregnancy Category D. There is evidence of fetal harm based on animal studies and its mechanism of. BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE is classified as Category A/B. No evidence of teratogenicity in first trimester; animal studies show no fetal harm. Second and third trimester risk is low due to minimal systemic absorption from topical use. No . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.